SCHEDULE: Soleus Capital Discloses 4.6% Stake in Praxis Precision
Beneficial Ownership Report (Schedule 13G Amendment)
Soleus Capital Master Fund and related entities report a passive 4.6% beneficial ownership in Praxis Precision Medicines, Inc.
Summary
- Soleus Capital Master Fund, L.P., along with its related entities Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, and Guy Levy, collectively reported beneficial ownership of 966,740 shares of common stock in Praxis Precision Medicines, Inc.
- This aggregate amount represents 4.6% of the Issuer's common stock outstanding.
- The percentage is calculated based on 21,045,781 shares of common stock outstanding as of July 31, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2025, filed on August 4, 2025.
- All reporting persons share both voting and dispositive power over the 966,740 shares.
- The shares are held directly by Soleus Capital Master Fund, L.P., with the other reporting persons disclaiming beneficial ownership except for Section 13(d) purposes.
- The filing indicates that the securities were not acquired and are not held for the purpose or effect of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: A Schedule 13G filing is a routine disclosure of passive beneficial ownership. The 4.6% stake is below the 5% threshold for active reporting, indicating a non-controlling interest. Without prior filings, it's neutral as it doesn't signal a significant change in investment thesis or company performance.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of passive beneficial ownership by an investment fund in a publicly traded biotechnology company. It does not provide specific insights into broader industry trends or competitive landscape beyond the investment itself.
Stakeholder Impact
- Minimal direct impact on shareholders, employees, customers, suppliers, or creditors as this is a passive ownership disclosure below the 5% threshold, indicating no intent to influence control.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which required the filing of this statement |
| 07/31/2025 | Date as of which the number of outstanding shares of common stock of Praxis Precision Medicines, Inc. was reported |
| 08/04/2025 | Date of filing of the Issuer's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2025 |
| 08/05/2025 | Date of signing of this Schedule 13G Amendment No. 1 |
Keywords
Praxis Precision Medicines, Soleus Capital, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Investment, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.